BIIBBiogen Continues To Decline After Friday’s RoutDid The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?Synageva Q1 Loss Narrower-than-Expected, Pipeline in Focus – Analyst Blog(Zacks)
In this week’s episode, Estimize is joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights.
In the episode, Joe discusses Biogen Inc (NASDAQ: BIIB) new drug, which could be the holy grail for biotech stocks. Leigh and Joe also chat about a hedge fund that seeks to make drug prices cheaper, and wrap things up with a complete earnings overview for the biotech sector.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
View original article: